<DOC>
	<DOCNO>NCT01382719</DOCNO>
	<brief_summary>This trial design evaluate efficacy safety 3 fix dose level bremelanotide , administer subcutaneously as-needed basis condition home use , treatment female sexual arousal disorder ( FSAD ) , hypoactive sexual desire disorder ( HSDD ) , mixed FSAD/HSDD premenopausal woman .</brief_summary>
	<brief_title>Bremelanotide Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Hypokinesia</mesh_term>
	<mesh_term>Sexual Dysfunctions , Psychological</mesh_term>
	<mesh_term>Sexual Dysfunction , Physiological</mesh_term>
	<mesh_term>alpha-MSH</mesh_term>
	<criteria>Female , least 21 year age , premenopausal Previously experience sexual arousal sexual activity and/or normal level desire past least 2 year . Willing engage sexual activity Currently stable relationship partner ( male female ) least 6 month . If subject male sexual partner , record score `` impotent '' `` minimally impotent '' Singlequestion Assessment ED . For least 6 month Screening , meet diagnostic criterion FSAD , HSDD , mixed FSAD/HSDD Has negative serum pregnancy test ( hCG ) Screening , subject 's partner male , use medically acceptable form contraception 3 month Screening ( Visit 1 ) , willing continue duration trial 1 month follow last dose trial drug . Has normal pelvic examination . At Screening document within 12 month Screening , : normal Pap test result without history positive HPV , dysplasia , ASCUS resolve treat ; Pap test result positive ASCUS negative HPV ; Pap test result positive HPV AND ASCUS dysplasia Pap condyloma present upon examination . At Screening Visit 2 , meet necessary questionnaire score . Medical condition unstable uncontrolled despite current therapy . History unresolved sexual trauma abuse . Pregnant nursing . Lifelong anorgasmia , vaginismus , sexual pain disorder , sexual aversion disorder , persistent sexual arousal disorder . Female sexual dysfunction cause untreated endocrine disease . Has follow : hepatitis C , infectious hepatitis , infectious blood disorder HIV ; myocardial infarction ; stroke . Has follow within 12 month Screening : chronic dyspareunia attributable vaginal dryness ; pelvic inflammatory disease ; chronic complicate UTI , active STD herpes condyloma ; cervical dysplasia , include LGSIL HGSIL and/or ASCUS HPV ; significant cervicitis manifest mucopurulent discharge cervix . Has follow within 6 month Screening : ≥ 2 outbreak genital herpes ; occurrence/recurrence clinically significant condyloma ; clinically unstable angina clinically unstable arrhythmia ; significant CNS diseases ; AST ALT concentration &gt; 3 time ULN ; serum creatinine &gt; 2.5 mg/dL ; clinically significant abnormal laboratory result . Has use prohibit medication within 3 month Screening : Has currently active moderate severe vaginitis clinically significant vaginal infection . Has one significant gynecologic condition . Is take receive treatment psychosis , bipolar disorder , depression , and/or alcohol/substance abuse within 6 month Screening . Is currently receive psychotherapy treatment FSAD and/or HSDD . Has following : Uncontrolled hypertension ; Systolic BP ≥ 140 mm Hg Screening ; Diastolic BP ≥ 90 mm Hg Screening ; Treatment hypertension change 3 month Screening . Had hysterectomy bilateral oophorectomy . Had hysterectomy without bilateral oophorectomy AND meet several criterion . Is take contraceptive affect menstrual cycle cause amenorrhea AND normal menstrual cycle start contraceptive medication .</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>FSAD</keyword>
	<keyword>HSDD</keyword>
	<keyword>female sexual dysfunction</keyword>
	<keyword>FSD</keyword>
	<keyword>Female Sexual Arousal Disorder</keyword>
	<keyword>Hypoactive Sexual Desire Disorder</keyword>
</DOC>